Background The long-term association between adrenal gland volume (AGV) and type 2 diabetes (T2D) remains unclear. We aimed to determine the association between deep learning-based AGV and current glycemic status and incident T2D.
Methods In this observational study, adults who underwent abdominopelvic computed tomography (CT) for health checkups (2011–2012), but had no adrenal nodules, were included. AGV was measured from CT images using a three-dimensional nnU-Net deep learning algorithm. We assessed the association between AGV and T2D using a cross-sectional and longitudinal design.
Results We used 500 CT scans (median age, 52.3 years; 253 men) for model development and a Multi-Atlas Labeling Beyond the Cranial Vault dataset for external testing. A clinical cohort included a total of 9708 adults (median age, 52.0 years; 5,769 men). The deep learning model demonstrated a dice coefficient of 0.71±0.11 for adrenal segmentation and a mean volume difference of 0.6± 0.9 mL in the external dataset. Participants with T2D at baseline had a larger AGV than those without (7.3 cm3 vs. 6.7 cm3 and 6.3 cm3 vs. 5.5 cm3 for men and women, respectively, all P<0.05). The optimal AGV cutoff values for predicting T2D were 7.2 cm3 in men and 5.5 cm3 in women. Over a median 7.0-year follow-up, T2D developed in 938 participants. Cumulative T2D risk was accentuated with high AGV compared with low AGV (adjusted hazard ratio, 1.27; 95% confidence interval, 1.11 to 1.46).
Conclusion AGV, measured using deep learning algorithms, is associated with current glycemic status and can significantly predict the development of T2D.
Hypothalamus and pituitary gland Big Data Articles (National Health Insurance Service Database)
Background Panhypopituitarism is a condition of combined deficiency of multiple pituitary hormones, which requires lifelong hormone replacement therapy. Hormone deficiency or inadequate hormone replacement may contribute to cardiovascular disease. Here, we aimed to investigate the burden of cardiovascular, cerebrovascular diseases and mortality in patients with panhypopituitarism.
Methods A total of 5,714 patients with panhypopituitarism were enrolled in the Korean National Health Insurance Service database from 2003 to 2020. Panhypopituitarism was defined according to the International Classification of Diseases, 10th Revision (ICD- 10) codes for hypopituitarism, pituitary adenoma, or craniopharyngioma and the continuous prescription of thyroid hormone and glucocorticoids. The risks of all-cause mortality, coronary artery disease (CAD), heart failure (HF), ischemic stroke, and intracranial hemorrhage were compared between patients with panhypopituitarism and age-, sex-, and index year-matched controls.
Results The mean age of patients with panhypopituitarism and matched controls was 55.1 years, and men accounted for 51.5%. Patients with panhypopituitarism showed significantly higher all-cause mortality compared to matched controls after adjustment for covariates (hazard ratio [HR], 2.18; 95% confidence interval [CI], 1.95 to 2.43 in men and HR, 3.09; 95% CI, 2.78 to 3.44 in women). Additionally, there were higher risks of CAD, HF, ischemic stroke, and intracranial hemorrhage in both sexes, except for CAD in men.
Conclusion Patients with panhypopituitarism have elevated risks of cardiovascular and cerebrovascular diseases as well as increased mortality. These risks are particularly prominent for all-cause mortality in women. Therefore, proactive monitoring for cardiovascular and cerebrovascular complications is required in patients with panhypopituitarism.
Background Hypercalcemia of malignancy (HCM), a major metabolic complication of cancer, is often managed with bisphosphonates (BP) and, increasingly, with denosumab. We aimed to compare the effectiveness and safety of denosumab with that of BP, with or without calcitonin, in treating HCM.
Methods This retrospective cohort study was conducted at a tertiary hospital from 2017 to 2022 and included 317 patients treated for HCM. Participants were divided into three treatment groups: denosumab, intravenous (IV) BP only, and IV BP combined with calcitonin. The primary outcomes measured were changes in calcium levels and the incidence of hypocalcemia. Analysis of covariance was used to adjust for age, sex, body mass index, creatinine level, type of malignancy, and the use of furosemide and steroids.
Results The mean participant age was 65 years, and 37.5% were female. After adjustment, both denosumab and IV BPs were found to effectively lower calcium levels. Denosumab led to a decrease of 2.0 mg/dL (−15.9%), while IV BP alone resulted in a reduction of 1.8 mg/dL (−13.9%). The largest reduction, of 2.7 mg/dL (−20.9%), occurred with IV BP and calcitonin. Both denosumab and IV BP+calcitonin yielded their lowest calcium levels within 48 hours, whereas the IV BP only group reached a nadir within 72 hours. Despite these differences in treatment effectiveness, hypocalcemia occurred significantly less frequently in the denosumab group compared to the other groups.
Conclusion Denosumab and IV BP were similarly effective in reducing calcium levels. However, IV BP combined with calcitonin yielded a more rapid and pronounced decrease.
Moon Young Oh, Hye-Mi Choi, Jinsun Jang, Heejun Son, Seung Shin Park, Minchul Song, Yoo Hyung Kim, Sun Wook Cho, Young Jun Chai, Woosung Chung, Young Joo Park
Endocrinol Metab. 2024;39(5):777-792. Published online October 14, 2024
Background We explored the utility of a small multi-gene DNA panel for assessing molecular profiles of thyroid nodules and influencing clinical decisions by comparing outcomes between tested and untested nodules.
Methods Between April 2022 and May 2023, we prospectively performed fine-needle aspiration (FNA) with gene testing via DNA panel of 11 genes (BRAF, RAS [NRAS, HRAS, KRAS], EZH1, DICER1, EIF1AX, PTEN, TP53, PIK3CA, TERT promoter) in 278 consecutive nodules (panel group). Propensity score-matching (1:1) was performed with 475 nodules that consecutively underwent FNA without gene testing between January 2021 and December 2021 (control group).
Results In the panel group, positive call rate for mutations was 41.7% (BRAF 16.2%, RAS 12.6%, others 11.5%, double mutation 1.4%) for all nodules, and 40.0% (BRAF 4.3%, RAS 19.1%, others 15.7%, double mutation 0.9%) for indeterminate nodules. Benign call rate was 69.8% for all nodules, and 75.7% for indeterminate nodules. In four nodules, additional TP53 (in addition to BRAF or EZH1) or PIK3CA (in addition to BRAF or TERT) mutations were co-detected. Sensitivity, specificity, positive predictive value, and negative predictive value were 80.0%, 53.3%, 88.1%, 38.1% for all nodules, and 78.6%, 45.5%, 64.7%, 62.5% for indeterminate nodules, respectively. Panel group exhibited lower surgical resection rates than the control group for all nodules (27.0% vs. 52.5%, P<0.001), and indeterminate nodules (23.5% vs. 68.2%, P<0.001). Malignancy risk was significantly different between the panel and control groups (81.5% vs. 63.9%, P=0.008) for all nodules.
Conclusion Our panel aids in managing thyroid nodules by providing information on malignancy risk based on mutations, potentially reducing unnecessary surgery in benign nodules or patients with less aggressive malignancies.
Citations
Citations to this article as recorded by
Great Debate: Molecular Testing and Extent of Surgery in Well-Differentiated Thyroid Cancer Cord Sturgeon, Ashok R. Shaha, Linwah Yip Annals of Surgical Oncology.2025; 32(7): 4597. CrossRef
Sun Kyung Baek, Seung Hun Lee, Seung Shin Park, Chang Ho Ahn, Sung Hye Kong, Won Woong Kim, Yu-Mi Lee, Su Jin Kim, Dong Eun Song, Tae-Yon Sung, Kyu Eun Lee, Jung Hee Kim, Kyeong Cheon Jung, Jung-Min Koh
Endocrinol Metab. 2024;39(5):803-812. Published online September 25, 2024
Background Adrenocortical carcinomas (ACCs) are rare tumors with aggressive but varied prognosis. Stage, Grade, Resection status, Age, Symptoms (S-GRAS) score, based on clinical and pathological factors, was found to best stratify the prognosis of European ACC patients. This study assessed the prognostic performance of modified S-GRAS (mS-GRAS) scores including modified grade (mG) by integrating mitotic counts into the Ki67 index (original grade), in Korean ACC patients.
Methods Patients who underwent surgery for ACC between January 1996 and December 2022 at three medical centers in Korea were retrospectively analyzed. mS-GRAS scores were calculated based on tumor stage, mG (Ki67 index or mitotic counts), resection status, age, and symptoms. Patients were divided into four groups (0–1, 2–3, 4–5, and 6–9 points) based on total mS-GRAS score. The associations of each variable and mS-GRAS score with recurrence and survival were evaluated using Cox regression analysis, Harrell’s concordance index (C-index), and the Kaplan–Meier method.
Results Data on mS-GRAS components were available for 114 of the 153 patients who underwent surgery for ACC. These 114 patients had recurrence and death rates of 61.4% and 48.2%, respectively. mS-GRAS score was a significantly better predictor of recurrence (C-index=0.829) and death (C-index=0.747) than each component (P<0.05), except for resection status. mS-GRAS scores correlated with shorter progression-free survival (P=8.34E-24) and overall survival (P=2.72E-13).
Conclusion mS-GRAS scores showed better prognostic performance than tumor stage and grade in Asian patients who underwent surgery for ACC.
Background Delayed postoperative hyponatremia (DPH) is the most common cause of readmission after pituitary surgery. In this study, we aimed to evaluate the cutoff values of serum copeptin and determine the optimal timing for copeptin measurement for the prediction of the occurrence of DPH in patients who undergo endoscopic transsphenoidal approach (eTSA) surgery and tumor resection.
Methods This was a prospective observational study of 73 patients who underwent eTSA surgery for pituitary or stalk lesions. Copeptin levels were measured before surgery, 1 hour after extubation, and on postoperative days 1, 2, 7, and 90.
Results Among 73 patients, 23 patients (31.5%) developed DPH. The baseline ratio of copeptin to serum sodium level showed the highest predictive performance (area under the curve [AUROC], 0.699), and its optimal cutoff to maximize Youden’s index was 2.5×10–11, with a sensitivity of 91.3% and negative predictive value of 92.0%. No significant predictors were identified for patients with transient arginine vasopressin (AVP) deficiency. However, for patients without transient AVP deficiency, the copeptin-to-urine osmolarity ratio at baseline demonstrated the highest predictive performance (AUROC, 0.725). An optimal cutoff of 6.5×10–12 maximized Youden’s index, with a sensitivity of 92.9% and a negative predictive value of 94.1%.
Conclusion The occurrence of DPH can be predicted using baseline copeptin and its ratio with serum sodium or urine osmolarity only in patients without transient AVP deficiency after pituitary surgery.
Citations
Citations to this article as recorded by
Impact Factors of Blood Copeptin Levels in Health and Disease States Yutong Wang, Shirui Wang, Siyu Liang, Xinke Zhou, Xiaoyuan Guo, Bochuan Huang, Hui Pan, Huijuan Zhu, Shi Chen Endocrine Practice.2024; 30(12): 1197. CrossRef
Adrenal incidentalomas represent an increasingly common clinical conundrum with significant implications for patients. The revised 2023 European Society of Endocrinology (ESE) guideline incorporates cutting-edge evidence for managing adrenal incidentalomas. This paper provides a concise review of the updated contents of the revised guideline. In the 2023 guideline, in patients without signs and symptoms of overt Cushing’s syndrome, a post-dexamethasone cortisol level above 50 nmol/L (>1.8 μg/dL) should be considered as mild autonomous cortisol secretion. Regarding the criteria of benign adrenal adenomas, a homogeneous adrenal mass with ≤10 Hounsfield units on non-contrast computed tomography requires no further follow-up, irrespective of its size. The updated guideline also discusses steroid metabolomics using tandem mass spectrometry to discriminate malignancy. It underscores the importance of high-volume surgeons performing adrenalectomy and emphasizes the pivotal role of a multidisciplinary team approach in deciding the treatment plan for indeterminate adrenal masses. The guideline advocates for more proactive surgical treatment for indeterminate adrenal masses in young patients (<40 years) and pregnant women. This review of the 2023 ESE guideline underscores the ongoing evolution of the adrenal incidentaloma management landscape, emphasizing the need for further research and adaptation of diagnostic and therapeutic strategies.
Citations
Citations to this article as recorded by
A deep learning algorithm for automated adrenal gland segmentation on non-contrast CT images Fanxing Meng, Tuo Zhang, Yukun Pan, Xiaojing Kan, Yuwei Xia, Mengyuan Xu, Jin Cai, Fangbin Liu, Yinghui Ge BMC Medical Imaging.2025;[Epub] CrossRef
A Secret Revealed: The Coexistence of a Pheochromocytoma and Independent Adrenocorticotropic Hormone-Secreting Cushing Syndrome Within the Same Adrenal Gland Sana Rafi, Meryam Alahyane, Ghizlane Elmghari, Nawal El Ansari, Fatim Zahra Hazmiri, Oumayma Ait Ouhssain, Hanane Rais Cureus.2025;[Epub] CrossRef
The Landmark Series: Evaluation and Management of Adrenal Incidentalomas Lily Owei, Heather Wachtel Annals of Surgical Oncology.2025; 32(7): 4712. CrossRef
Management of adrenal incidentalomas: who, why and how? Marta Araujo-Castro, María Bernarda Iriarte-Durán, Paola Parra-Ramírez, Sara Donato Current Opinion in Endocrinology, Diabetes & Obesity.2025;[Epub] CrossRef
Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [18F]Fluorodeoxyglucose positron emission tomography use, honed on adrenocortical carcinoma Ioannis Ilias, Georgios Meristoudis World Journal of Clinical Oncology.2025;[Epub] CrossRef
Personalized Management of Malignant and Non-Malignant Ectopic Mediastinal Thyroid: A Proposed 10-Item Algorithm Approach Mara Carsote, Mihai-Lucian Ciobica, Oana-Claudia Sima, Adrian Ciuche, Ovidiu Popa-Velea, Mihaela Stanciu, Florina Ligia Popa, Claudiu Nistor Cancers.2024; 16(10): 1868. CrossRef
Temporal trends in clinical features of patients with primary aldosteronism over 20 years Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim Hypertension Research.2024; 47(8): 2019. CrossRef
Steroid Profiling in the Differential Diagnosis of Cushing's Syndrome and Diagnosis of MACS A. Nankova, T. Kamenova, V. Vasilev, At. Elenkova, D. Svinarov, G. Kirilov, S. Zaharieva Acta Medica Bulgarica.2024; 51(2): 1. CrossRef
Adrenal incidentalomas Ivana Ságová Vnitřní lékařství.2024; 70(5): E9. CrossRef
Ectopic Mediastinal Thyroid: A Crossroad Between a Multi-Layered Endocrine Perspective and a Contemporary Approach in Thoracic Surgery Claudiu Nistor, Mihai-Lucian Ciobica, Oana-Claudia Sima, Anca-Pati Cucu, Florina Vasilescu, Lucian-George Eftimie, Dana Terzea, Mihai Costachescu, Adrian Ciuche, Mara Carsote Life.2024; 14(11): 1374. CrossRef
Mature Adrenal Ganglioneuroma With Lipomatous Content: A Radiological and Histopathological Diagnostic Challenge Mohammed Lameir Hussein, Shams O Alkhateeb, Jouhar J Kolleri, Ala' Saleem Abu-Dayeh, Khaled Murshed, Nabil Sherif Mahmood Cureus.2024;[Epub] CrossRef
Comparative Analysis of Liquid Chromatography-Tandem Mass Spectrometry and Radioimmunoassay in Determining Plasma Aldosterone Concentration and Plasma Renin Activity for Primary Aldosteronism Screening So Yoon Kwon, Kyeong-Jin Kim, Soo-Youn Lee, Jae Hyeon Kim Endocrinology and Metabolism.2024; 39(6): 965. CrossRef
Background Dual-energy X-ray absorptiometry (DXA) is the most widely used method for evaluating muscle masses. The aim of this study was to investigate the agreement between muscle mass values assessed by two different DXA systems.
Methods Forty healthy participants (20 men, 20 women; age range, 23 to 71 years) were enrolled. Total and regional body compositional values for fat and lean masses were measured consecutively with two DXA machines, Hologic Horizon and GE Lunar Prodigy. Appendicular lean mass (ALM) was calculated as the sum of the lean mass of four limbs.
Results In both sexes, the ALM values measured by the GE Lunar Prodigy (24.8±4.3 kg in men, 15.8±2.9 kg in women) were significantly higher than those assessed by Hologic Horizon (23.0±4.0 kg in men, 14.8±3.2 kg in women). Furthermore, BMI values or body fat (%), either extremely higher or lower levels, contributed greater differences between two systems. Bland-Altman analyses revealed a significant bias between ALM values assessed by the two systems. Linear regression analyses were performed to develop equations to adjust for systematic differences (men: Horizon ALM [kg]=0.915×Lunar Prodigy ALM [kg]+0.322, R2=0.956; women: Horizon ALM [kg]=1.066×Lunar Prodigy ALM [kg]–2.064, R2=0.952).
Conclusion Although measurements of body composition including muscle mass by the two DXA systems correlated strongly, significant differences were observed. Calibration equations should enable mutual conversion between different DXA systems.
Citations
Citations to this article as recorded by
Development of an Algorithm to Predict Appendicular Lean Mass Index From Regional Spine and Hip Dxa Scans Krista Rossum, Mackenzie R. Alexiuk, Clara Bohm, William D. Leslie, Navdeep Tangri Journal of Clinical Densitometry.2025; 28(2): 101560. CrossRef
Comparing digital anthropometrics from mobile applications to reference methods: a scoping review Irismar Gonçalves Almeida da Encarnação, Matheus Santos Cerqueira, Paulo Henrique Ribeiro Fernandes Almeida, Cláudia Eliza Patrocínio de Oliveira, Analiza Mónica Lopes de Almeida Silva, Diego Augusto Santos Silva, Steven B. Heymsfield, Osvaldo Costa Morei European Journal of Clinical Nutrition.2025;[Epub] CrossRef
Sarcopenia, Muscle Mass and Protein Intake in Adults Older Than 65 Years After Earlier Bariatric Surgery Gabriël Eksteen, Tim Vanuytsel, Roman Vangoitsenhoven, Ann Mertens, Matthias Lannoo, Ellen De Leus, Bart Van der Schueren, Christophe Matthys Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Ultrasound-Derived Skinfolds in Anthropometric Predictive Equations Overestimate Fat Mass: A Validation Study Using a Four-Component Model Giuseppe Cerullo, Martino V. Franchi, Alessandro Sampieri, Francesco Campa, Antonio Paoli Nutrients.2025; 17(11): 1881. CrossRef
Evaluating the Accuracy and Clinical Utility of Bioelectrical Impedance Analysis (BIA) Devices for Body Composition Measurements in Clinical Practice: Comparison of Four Types of BIA Equipment and Dual-Energy X-ray Absorptiometry So Youn LEE, Hwayeon SUN, Sung Hwan BAE, Ju Yeon SON, Byungwook YOO Korean Journal of Health Promotion.2025; 25(2): 50. CrossRef
Glycaemic Response to a Nut-Enriched Diet in Asian Chinese Adults with Normal or High Glycaemia: The Tū Ora RCT Ivana R. Sequeira-Bisson, Louise W. Lu, Marta P. Silvestre, Lindsay D. Plank, Nikki Middleditch, Alejandra Acevedo-Fani, Amber Parry-Strong, Kieren G. Hollingsworth, Alexander Tups, Jennifer L. Miles-Chan, Jeremy D. Krebs, Meika Foster, Sally D. Poppitt Nutrients.2024; 16(13): 2103. CrossRef
The usefulness of total body protein mass models for adolescent athletes Analiza M. Silva, Francesco Campa, Luís B. Sardinha Frontiers in Nutrition.2024;[Epub] CrossRef
Standardization of body composition parameters between GE Lunar iDXA and Hologic Horizon A and their clinical impact Colin Vendrami, Guillaume Gatineau, Elena Gonzalez Rodriguez, Olivier Lamy, Didier Hans, Enisa Shevroja JBMR Plus.2024;[Epub] CrossRef
Impaired Muscle Parameters in Individuals With Premature Ovarian Insufficiency: A Pilot Study Navira Samad, Wei Ling Chiu, Hanh H Nguyen, Zhong X Lu, Margaret Zacharin, Peter R Ebeling, Helena Teede, David Scott, Frances Milat, Amanda J Vincent Journal of the Endocrine Society.2024;[Epub] CrossRef
Comparison of bioelectrical impedance analysis and dual-energy X-ray absorptiometry for the diagnosis of sarcopenia in the older adults with metabolic syndrome: equipment-specific equation development Younji Kim, Jaewon Beom, Sang Yoon Lee, Hak Chul Jang, Keewon Kim, Miji Kim, Ga Yang Shim, Chang Won Won, Jae-Young Lim Aging Clinical and Experimental Research.2024;[Epub] CrossRef
Total and regional appendicular skeletal muscle mass prediction from dual-energy X-ray absorptiometry body composition models Cassidy McCarthy, Grant M. Tinsley, Anja Bosy-Westphal, Manfred J. Müller, John Shepherd, Dympna Gallagher, Steven B. Heymsfield Scientific Reports.2023;[Epub] CrossRef
Cross-Calibration of iDXA and pQCT Scanners at Rural and Urban Research Sites in The Gambia, West Africa Mícheál Ó Breasail, Ramatoulie Janha, Ayse Zengin, Camille Pearse, Landing Jarjou, Ann Prentice, Kate A. Ward Calcified Tissue International.2023; 112(5): 573. CrossRef
Estimation of Absolute and Relative Body Fat Content Using Noninvasive Surrogates: Can DXA Be Bypassed? David J. Greenblatt, Christopher D. Bruno, Jerold S. Harmatz, Bess Dawson‐Hughes, Qingchen Zhang, Chunhui Li, Christina R. Chow The Journal of Clinical Pharmacology.2023;[Epub] CrossRef